Cases That Test Your Skills

The paranoid business executive

Author and Disclosure Information

 

References

TREATMENT Stable on olanzapine

During his first visit to the outpatient clinic 4 weeks after being discharged, Mr. R reports that he has successfully returned to work, and his paranoia has completely resolved. He continues to take olanzapine, 10 mg nightly, and has restarted clomiphene, 100 mg/d.

During this outpatient follow-up visit, Mr. R attributes his manic episode to an adverse reaction to amoxicillin/clavulanate, and requests to be tapered off olanzapine. After he and his psychiatrist discuss the risk of relapse in untreated bipolar disorder, olanzapine is reduced to 7.5 mg at bedtime with a plan to taper to discontinuation.

At his second follow-up visit 1 month later, Mr. R has also stopped clomiphene and is taking a herbal supplement instead, which he reports is helpful for his fatigue. He says his mood is stable and denies experiencing any manic or depressive symptoms. Olanzapine is discontinued at this visit.

OUTCOME Lasting euthymic mood

Mr. R agrees to our recommendation of continuing to monitor him every 3 months for at least 1 year. We provide him and his wife with education about early warning signs of mood instability. Eight months after his manic episode, Mr. R no longer receives any psychotropic medications and shows no signs of mood instability. His mood remains euthymic and he is able to function well at work and in his personal life.

Bottom Line

‘Antibiomania’ describes manic episodes that coincide with antibiotic usage. This adverse effect is rare but should be considered in patients who present with unexplained first-episode mania, particularly those with an initial onset of mania after early adulthood.

Continue to: Related Resources

Pages

Recommended Reading

Emotional processing of scenes in bipolar I appears intact
MDedge Psychiatry
Blood-brain barrier imaging could predict disease progression in bipolar
MDedge Psychiatry
Disentangling sleep problems and bipolar disorder
MDedge Psychiatry
Blunted ventral striatal responses found in remitted bipolar I
MDedge Psychiatry
Alkermes submits NDA for new schizophrenia, bipolar I treatment
MDedge Psychiatry
Higher risk of bipolar disorder, depression, anxiety found with autism
MDedge Psychiatry
High recurrence, shortening cycle length in bipolar disorder associated with several biomarkers
MDedge Psychiatry
Abnormal gaze processing found in patients with bipolar disorder
MDedge Psychiatry
Schizophrenia, bipolar disorder associated with increased risk of secondary TD
MDedge Psychiatry
Valproic acid-induced hyperammonemic encephalopathy
MDedge Psychiatry